A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
| Status: | Terminated |
|---|---|
| Conditions: | Blood Cancer, Hematology, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | March 2007 |
| End Date: | June 2007 |
This open-label study will assess anti-tumor activity and safety of belinostat in
combination with bortezomib (Velcade®) in multiple myeloma patients refractory to or
relapsed from at least one prior bortezomib-containing regimen. Subjects will be
administered both PXD101 and bortezomib on the same days: i.e. days 1, 4, 8, and 11 of a
3-week cycle, for up to 8 cycles.
combination with bortezomib (Velcade®) in multiple myeloma patients refractory to or
relapsed from at least one prior bortezomib-containing regimen. Subjects will be
administered both PXD101 and bortezomib on the same days: i.e. days 1, 4, 8, and 11 of a
3-week cycle, for up to 8 cycles.
Inclusion Criteria:
- Diagnosis of multiple myeloma.
- Status of refractory to or relapsed from at least one prior bortezomib-containing
regimen.
- Progressive disease.
- Age >= 18 years.
- Karnofsky performance status >= 60%
- Acceptable liver function:
- Bilirubin =< 1.5 x ULN (upper limit of normal)
- Aspartate transaminase (AST) and alanine transaminase (ALT) =< 3 x ULN
- Acceptable hematologic status:
- Absolute Neutrophil Count (ANC) >= 1.5 x 109/L
- Platelet count >= 100 x 109/L
- Hemoglobin >= 9 g/dL
- Coagulation status PT-INR/PTT =< 1.5 x ULN or in the therapeutic range if on
anticoagulation therapy. (PT-INR/PTT= prothrombin - international normalized
ratio / prothrombin time)
- Serum potassium within normal range.
- Estimated life expectancy greater than 3 months.
- Signed, written IRB (institutional Review Board)-approved informed consent.
Exclusion Criteria:
- Non-secretory multiple myeloma or symptomatic amyloidosis.
- Hypersensitivity to bortezomib, boron, or mannitol.
- Less than 4 weeks since prior chemotherapy, radiotherapy, endocrine therapy, or
immunotherapy, except if disease is rapidly progressing.
- Less than 4 weeks since prior use of other investigational agents.
- Serious concomitant systemic disorders (e.g. active infection).
- Significant cardiovascular disease.
- Marked baseline prolongation of QT/QTc (corrected QT interval)interval.
- Central nervous system disorders requiring neuroleptics / anti-convulsants.
- Peripheral sensory neuropathy of ≥ Grade 2
- Renal insufficiency defined as a creatinine clearance of < 30 ml/min.
- Non-willingness to use effective contraceptive methods for patients of child-bearing
age / potential.
- Pregnant or breast-feeding women.
- Known HIV positivity.
- Prior treatment with belinostat (PXD101), or any other HDAC (histone deacetylase)
inhibitor.
- Altered mental status which precludes an understanding of the Informed Consent
Document.
We found this trial at
3
sites
Center for Cancer & Blood Disorders Widely recognized for its compassionate, expert care, the Center...
Click here to add this to my saved trials
Baylor University Medical Center Baylor University Medical Center in Dallas, TX is ranked nationally in...
Click here to add this to my saved trials
Click here to add this to my saved trials